Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The ACXP news feed on Stock Titan brings together company press releases, scientific updates and regulatory disclosures that highlight progress across its DNA polymerase IIIC (pol IIIC) inhibitor platform.
Readers can follow detailed announcements on ibezapolstat, Acurx’s lead oral Gram-Positive Selective Spectrum (GPSS®) antibiotic candidate for Clostridioides difficile Infection (CDI). News items include Phase 2 clinical data, preparations for international Phase 3 trials, and regulatory milestones such as FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations, EMA scientific advice, and a positive opinion from the EMA Paediatric Committee on the Pediatric Investigation Plan for ibezapolstat in children.
The ACXP news stream also covers developments in Acurx’s preclinical DNA pol IIIC pipeline, including patents granted in multiple jurisdictions for the ACX-375C program, collaborations with Leiden University Medical Center (LUMC) on structural biology of pol IIIC, and presentations at major scientific meetings like IDWeek and other infectious disease conferences. These updates often describe new data on microbiome selectivity, bile acid profiles, and potential class effects across the company’s inhibitor series.
Investors and observers can track capital markets and corporate actions reported by Acurx, such as warrant inducement transactions, equity line financings, and a 1-for-20 reverse stock split undertaken to support continued Nasdaq listing. For anyone monitoring antibiotic innovation against Gram-positive priority pathogens, the ACXP news page provides an organized view of Acurx’s clinical, regulatory, scientific and financing milestones over time.
Acurx Pharmaceuticals (Nasdaq: ACXP) announced that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at the Alliance Global Partners Healthcare Company Showcase on Wednesday, May 24, 2025.
A replay will be available under the News / Events tab of the Acurx website at www.acurxpharma.com following the event.
Acurx Pharmaceuticals (NASDAQ: ACXP) will present at the Market Movers Investor Summit on Tuesday, May 5, 2026 at 5:20 PM ET at the historic Bank of New York, 48 Wall Street, New York.
David P. Luci, President and CEO, is scheduled to give the company presentation. Attendance requires an invitation via the summit website.
Acurx Pharmaceuticals (NASDAQ: ACXP) will discuss its first quarter 2026 financial results on Tuesday, May 12, 2026 at 8:00 a.m. ET before U.S. markets open. David P. Luci, president and CEO, and Robert G. Shawah, CFO, will host a conference call and provide a business update. Participant dial-in details and international toll-free numbers are available; U.S. access ID is 13760162.
Acurx Pharmaceuticals (NASDAQ: ACXP) closed a registered direct offering on April 16, 2026, selling 825,085 shares (or pre-funded warrants) at $3.03 per share for aggregate gross proceeds of approximately $2.5 million.
In a concurrent private placement the company issued immediately exercisable short-term warrants to purchase up to 1,650,170 shares at an exercise price of $2.78, exercisable for 24 months, which could raise an additional ~$4.6 million if fully exercised.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced a registered direct offering to sell 825,085 shares (or pre-funded warrants) at $3.03 per share and a concurrent private placement of short-term warrants to purchase up to 1,650,170 shares at $2.78 per warrant.
The offering is expected to close on or about April 16, 2026, providing approximately $2.5 million of upfront gross proceeds and up to $4.6 million additional proceeds if warrants are fully exercised, for total potential gross proceeds of $7.1 million.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced on March 30, 2026 that the Korean Intellectual Property Office granted a patent covering DNA Polymerase IIIC inhibitors, including compositions‑of‑matter, methods of use, and pharmaceutical formulations.
This grant adds to Acurx's expanding patent estate protecting its ACX‑375C program, following four U.S. patents and granted patents in Israel, Japan, India, Australia, and other jurisdictions. The company said its lead DNA pol IIIC inhibitor, ibezapolstat, is positioned to enter international Phase 3 pivotal registration trials in the U.S. and EU for oral acute C. difficile infection and that a trial in multiply‑recurrent CDI is starting up.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported full-year 2025 results and a business update on March 13, 2026. Key items: cash $7.6M, gross equity-line proceeds ~$4.0M in 2025, net loss $8.0M for 2025, and 2,348,113 shares outstanding.
Clinical highlights include a planned open-label 20-patient rCDI pilot, Phase 2 ibezapolstat results (96% clinical cure of 26 patients, no recurrence), a new USPTO patent to Dec 2039, and structural biology publication supporting the Pol IIIC inhibitor program.
Acurx (Nasdaq: ACXP) announced a new open-label pilot trial of ibezapolstat in multiply-recurrent C. difficile infection (rCDI) and said its broader CDI program is ready to advance to Phase 3 international trials, subject to funding.
Key details: up to 20 patients in the pilot, first patient expected to enroll in Q4 2026, prior Phase 2 results showed high clinical cure and low recurrence, and Acurx holds FDA QIDP and Fast-Track plus EMA SME designations.
Acurx Pharmaceuticals (NASDAQ: ACXP) will report full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 a.m. ET before U.S. markets open. Management will host a conference call to review results and provide a business update.
Call hosts: David P. Luci, President and CEO, and Robert G. Shawah, CFO. Toll-free U.S. access and international participant numbers are provided for investors.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the USPTO granted U.S. patent US 12,534,470 covering DNA Polymerase IIIC inhibitors, including compositions, methods of use, and pharmaceutical formulations. This adds to four U.S. patents and granted patents in Israel, Japan, India, and Australia.
The company says its lead DNA pol IIIC inhibitor, ibezapolstat, is Phase 3-ready for oral C. difficile treatment, and preclinical compounds show microbiome selectivity versus linezolid and systemic absorption supporting potential oral and parenteral use across multiple serious infection indications.